<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355273</url>
  </required_header>
  <id_info>
    <org_study_id>20200420</org_study_id>
    <nct_id>NCT04355273</nct_id>
  </id_info>
  <brief_title>Effects of Different Concentrations of Pressurized-heparin Flushing Fluid on Coagulation and Platelet Function Monitored by the Sonoclot Analyzer</brief_title>
  <official_title>Effects of Different Concentrations of Pressurized-heparin Flushing Fluid on Coagulation and Platelet Function Monitored by the Sonoclot Analyzer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin diluent or normal saline is generally used as the arterial tube flushing in clinical
      practice, but there is no consensus on the choice of flushing fluid. Heparin can affect the
      blood coagulation function, and even lead to heparin-related thrombocytopenia, increasing the
      risk of perioperative embolism. Sonoclot is a blood viscoelasticity test, which can provide
      comprehensive information on the coagulation's cascade and the entire process and be quicker
      and more effective than routine laboratory coagulation tests. In this research, the
      coagulation and platelet function analyzer called Sonoclot is used to evaluate the effect of
      different concentrations of pressurized heparin on the coagulation and platelet function of
      perioperative patients, which can provide a reference for the clinical choice of appropriate
      arterial flushing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The level of glass bead Activated Clotting Time</measure>
    <time_frame>through study completion, an average of 3 minute</time_frame>
    <description>10 min after the vein puncture, 2 h after skin incision and at the end of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of glass bead Clot Rate</measure>
    <time_frame>through study completion, an average of 3 minute</time_frame>
    <description>10 min after the vein puncture, 2 h after skin incision and at the end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of glass bead Platelet Function</measure>
    <time_frame>through study completion, an average of 3 minute</time_frame>
    <description>10 min after the vein puncture, 2 h after skin incision and at the end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of platelet count</measure>
    <time_frame>through study completion, an average of 2 minute</time_frame>
    <description>24 h after surgery and 48 h after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequencies of hand positional changes and manual artery flushing</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of infusion volume, blood loss, urine volume</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The appearance of local complications of arterial puncture</measure>
    <time_frame>within 24 h after surgery</time_frame>
    <description>Yes or No</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Heparin</condition>
  <condition>Perioperative</condition>
  <arm_group>
    <arm_group_label>Heparin with a concentration of 2 U/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin dilution is placed in a pressure bag with a pressure of 300 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin with a concentration of 4 U/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin dilution is placed in a pressure bag with a pressure of 300 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline is placed in a pressure bag with a pressure of 300 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube</description>
    <arm_group_label>Heparin with a concentration of 2 U/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube</description>
    <arm_group_label>Heparin with a concentration of 4 U/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of gastrointestinal cancer

          -  Ages ranged from 18 to 75

          -  ASA I~III

        Exclusion Criteria:

          -  Pregnancy

          -  modified Allen Test negative

          -  history of taking anti-platelet drugs such as aspirin one week before surgery, heparin
             allergy and thrombotherapy

          -  two failed catheterizations of the same artery

          -  significant diseases in liver and kidney function

          -  refusal of patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University, Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

